Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Israel - English - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Israel - English - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine dr teva is indicated for:- the treatment of major depressive episodes. - the management of neuropathic pain associated with diabetic peripheral neuropathy. - the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia. - the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low ‎back pain (clbp) and chronic pain due to osteoarthritis.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine dr teva is indicated for:- the treatment of major depressive episodes. - the management of neuropathic pain associated with diabetic peripheral neuropathy. - the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia. - the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low ‎back pain (clbp) and chronic pain due to osteoarthritis.

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine is indicated for the treatment of: - major depressive disorder [see clinical studies (14.1)] - generalized anxiety disorder [see clinical studies (14.2)] - diabetic peripheral neuropathy [see clinical studies (14.3)] - chronic musculoskeletal pain [see clinical studies (14.5)]         monoamine oxidase inhibitors (maois) -the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] .         starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)].         pregnancy

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine is indicated for the treatment of: - major depressive disorder in adults - generalized anxiety disorder in adults and pediatric patients 7 years of age and older. diabetic peripheral neuropathic pain in adults fibromyalgia in adults chronic musculoskeletal pain in adults - diabetic peripheral neuropathic pain in adults - fibromyalgia in adults - chronic musculoskeletal pain in adults additional pediatric use information is approved for eli lilly and company, inc.’s cymbalta (duloxetine) delayed-release capsules. however, due to eli lilly and company inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administrati

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine is indicated for the treatment of: additional pediatric use information is approved for eli lilly and company, inc.’s cymbalta (duloxetine) delayed-release capsules. however, due to eli lilly and company inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . risk summary data from a postmarketing retrospect

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder [see clinical studies ( 14.1)] - generalized anxiety disorder [see clinical studies ( 14.2)] - diabetic peripheral neuropathy [see clinical studies ( 14.3)] - chronic musculoskeletal pain [see clinical studies ( 14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.8) and warnings and precautions ( 5.4)]. starting duloxetine in a patient who is being treated with maois such a

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules, usp are indicated for the treatment of: - major depressive disorder [see clinical studies 14.1] - generalized anxiety disorder [see clinical studies 14.2] - diabetic peripheral neuropathy [see clinical studies 14.3] - chronic musculoskeletal pain [see clinical studies 14.5] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin